COBALT advised Practica Capital on investing in a European pharmaceutical marketplace Pipelinepharma

COBALT advised Practica Capital which led and closed the European B2B pharmaceutical marketplace Pipelinepharma €1.3M venture seed round. Iron Wolf Capital, Pandos and a group of angel investors also participated in the funding round.

Pipelinepharma is a B2B pharmaceutical marketplace that connects pharmaceutical manufacturers with distributors around the globe. The marketplace has already facilitated pharmaceutical product licensing, supply, acquisition deals of more than €200M in value covering more than 30 markets on 5 continents.

The investment will be realized to attract top talent to the engineering, data science, pharmaceutical sales and marketing teams, further building upon Pipelinepharma’s mission – to make pharmaceutical products more affordable for every human on the planet.

“We are certain that future pharmaceutical B2B partnerships deals will take place online. The disruption of traditional dealmaking due to the pandemic only accelerated the shift to digital channels. Our database of vetted pharmaceutical products and qualified manufacturers accelerates product discovery, streamlines negotiations and significantly reduces business development costs”,- noted co-founder and CEO of Pipelinepharma Mindaugas Zagorskis.

COBALT advised Practica Capital on the structuring of the transaction, drafted transaction documentation, represented the client in negotiations, conducted legal due diligence and advised on other transaction-related matters. COBALT team was comprised of Partners Akvilė Bosaitė and Eva Suduiko.